Logo

BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

Share this

BMS Presents Results of Opdivo (nivolumab) + CT in P-III CheckMate-816 Trial for Resectable NSCLC at AACR2021

Shots:

  • The P-III CheckMate-816 study involves assessing Opdivo (360mg) + CT (q3w for 3 doses) vs CT- followed by surgery as a neoadjuvant treatment in 358 patients with resectable stage Ib to IIIa NSCLC
  • The study met its 1EPs- i.e. improvement in pCR (24% vs 2.2%) and showed improvement in 2EPs i.e. MPR (36.9% vs 8.9)- patients who underwent surgery showed that Opdivo did not decrease the feasibility of performing surgery (83% vs 75%)- patients whose tumors were R0 (83% vs 78%)
  • Opdivo-based treatments showed benefits in 4 P-III clinical trials in early-stage cancers- including lung cancer- bladder cancer- esophageal/GEJ cancer and melanoma

  Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions